Steve E. Krognes, CFO and Treasurer at Denali Therapeutics Inc. (DNLI), sold 100,000 shares at $70.10 ($7.1M) on 2021-01-15, disclosed to the SEC on 2021-01-20.
Open-market sale of $7.1M DNLI by CFO and Treasurer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $70.10 | 14,801 | $1.0M | 14.5% |
| 2 | $70.10 | 14,801 | $1.0M | 14.5% |
| 3 | $70.96 | 12,981 | $921K | 12.9% |
| 4 | $70.96 | 12,981 | $921K | 12.9% |
| 5 | $71.99 | 8,071 | $581K | 8.1% |
| 6 | $71.99 | 8,071 |
| $581K |
| 8.1% |
| 7 | $73.01 | 14,147 | $1.0M | 14.5% |
| 8 | $73.01 | 14,147 | $1.0M | 14.5% |
| Total | $71.45 avg | 100,000 | $7.1M | 100% |
| Filing → |
| DNLI | SELL | 2025-01-08 | $139K | — | Filing → |
| DNLI | SELL | 2025-01-03 | $608K | — | Filing → |
| DNLI | SELL | 2024-10-02 | $871K | — | Filing → |